Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB102 in celiac disease on gluten-free diet
NCT06982963Phase 2Recruiting
- Sponsor
- Forte Biosciences, Inc.
- Start
- Aug 2025
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FB102 in celiac disease (3 arms), sponsored by Forte Biosciences, Inc. Primary endpoint: Villous Crypt Intraepithelial Lymphocyte at 78 days. Started Aug 2025; status: recruiting.
02
Drugs
FB102
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT06982963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982963.